Notice of Special Interest regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus by NIAID and NIGMS
The National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.
The National Institute of General Medical Sciences (NIGMS) is specifically interested in the incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
Therefore, NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV), offering competitive revisions to active grants addressing research objectives described below.
In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
- Studies to identify optimal 2019-nCoV in vitro culture requirements and conditions;
- Development of reagents and assays for virus characterization;
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- Studies to identify viral epitopes critical for binding neutralization;
- Studies to examine virus stability and persistence;
- Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins;
- Development of animal models of 2019-nCoV infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
- Studies on the evolution and emergence of 2019-nCoV viruses including the identification of factors that affect viral host-range and virulence;
- Virologic and serologic surveillance studies of the distribution and natural history of 2019-nCoV viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
- Development of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV;
- Development of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications;
- Identification and evaluation of the innate, cellular and humoral immune responses to 2019-nCoV infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to 2019-nCoV and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
- Development of 2019-nCoV vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.
Read more here.
Deadline February 6, 2021.